Paclitaxel amorphous solid dispersion oral preparation and preparation method thereof

Through amorphous solid dispersion technology, nanoparticles were formed using a carrier of vitamin E polyethylene glycol succinate and cocamidopropyl betaine combined with surfactant, which solved the problem of difficulty in absorbing paclitaxel in the gastrointestinal tract, significantly It improves its oral bioavailability and overcomes the barriers of metabolic and efflux pumps, achieving efficient drug absorption.

CN118948776AActive Publication Date: 2024-11-15MINZU UNIVERSITY OF CHINA

Patent Information

Application Number
CN202411314389.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-20
Publication Date
2024-11-15
Estimated Expiration
2044-09-20

AI Technical Summary

Technical Problem

The low water solubility and strong lipophilicity of paclitaxel make it difficult to absorb in the gastrointestinal tract and is easily affected by cytochromase P450 metabolism and P-gp efflux pump function. The existing technology is difficult to effectively overcome these barriers, resulting in oral biologics. Low utilization.

Method used

Using amorphous solid dispersion technology, vitamin E polyethylene glycol succinate and cocamidopropyl betaine as carriers, combined with the zwitterionic surfactant cocamidopropyl betaine, forming nanoparticles, improving the drug The solubility and mucus permeability of the p-gp efflux activity is inhibited and drug absorption is promoted.

Benefits of technology

The oral bioavailability of paclitaxel was significantly improved, the maximum blood drug concentration was significantly increased, and the absolute bioavailability was increased to 86.4%. The preparation process of the preparation was simple, safe, and low toxicity, avoiding liver metabolic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005051714580000101
    Figure BDA0005051714580000101
  • Figure BDA0005051714580000111
    Figure BDA0005051714580000111
  • Figure HDA0005051714590000011
    Figure HDA0005051714590000011
Patent Text Reader

Abstract

The invention discloses a paclitaxel amorphous solid dispersion oral preparation and a preparation method thereof. The paclitaxel amorphous solid dispersion oral preparation disclosed by the invention is shown as I) or II): I) the paclitaxel amorphous solid dispersion oral preparation contains paclitaxel and cocamidopropyl betaine (CAPB); and II) the composition comprises paclitaxel, vitamin E polyethylene glycol succinate (TPGS) and cocamidopropyl betaine (CAPB). According to the invention, CAPB or TPGS and CAPB are combined to be used as a paclitaxel carrier, and the medicine is uniformly dispersed in the auxiliary material in an amorphous state, so that the oral bioavailability of paclitaxel can be remarkably improved. When the paclitaxel / TPGS / CAPB amorphous solid dispersion is prepared, the paclitaxel / TPGS / CAPB amorphous solid dispersion with good uniformity can be obtained only by dissolving the medicines and the auxiliary materials in ethanol together and removing the solvent through a simple spray drying or rotary evaporation technology and the like, the process is simple, and the quality is controllable.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and in particular relates to a paclitaxel amorphous solid dispersion oral preparation and a preparation method thereof. Background Art

[0002] Paclitaxel is a broad-spectrum anti-tumor drug that inhibits tumor cell proliferation mainly by promoting the aggregation of microtubules during cell mitosis and inhibiting their depolymerization. Paclitaxel is widely used in the treatment of ovarian cancer, breast cancer, non-small cell lung cancer and other cancers as a first-line anticancer drug in clinical practice. At present, paclitaxel, albumin paclitaxel, and paclitaxel liposomes commonly used in clinical practice are all administered intravenously. However, intravenous paclitaxel needs to be wrapped in castor oil, which may cause hypersensitivity reactions; in addition, long-term intravenous use of paclitaxel requires a high economic cost. Patient compliance with intravenous drip is also extremely poor. Oral administration has become the first choice for formulation development due to its convenient administration, painless, relatively safe, patient self-administration, and easy storage and transportation.

[0003] However, there are certain difficulties in developing oral paclitaxel. First of all, from the perspective of the physical and chemical properties of the drug itself, paclitaxel has extremely low water solubility (~0.12μg / mL), strong lipophilicity (log P: 3.96), poor gastrointestinal permeability, and belongs to BCS IV class drugs. Secondly, from the perspective of the physiological and biochemical barriers of the human gastrointestinal tract, the gastrointestinal tract has a rich enzyme environment, which causes the drug to be easily degraded and ineffective after entering the gastrointestinal tract. The surface of gastrointestinal epithelial cells is covered with a layer of mucus secreted by goblet cells. Because its components such as mucin are negatively charged, positively charged or hydrophobic nanomedicines are easily entangled by mucus, resulting in inability to penetrate the surface of the intestinal villi for effective absorption. Intestinal epithelial tissue is mainly composed of intestinal epithelial cells, and the tight junctions between cells form a serious cell barrier to the absorption of nanomedicines, resulting in low bioavailability. Finally, from the perspective of drug absorption mechanism, paclitaxel is easily metabolized by cytochrome P450 (CYP) 2C8 in the liver; paclitaxel is also a p-glycoprotein (P-gp) substrate, and P-gp, which is highly expressed in the gastrointestinal tract and tumor cells, has an efflux pump function, which makes it difficult for paclitaxel to reach an effective therapeutic concentration in tumor cells. Taking all the above factors into consideration, although oral paclitaxel has been developed for many years, there is still no oral paclitaxel drug on the market in China because its oral absorption problem has not been solved.

[0004] In view of the above factors that make paclitaxel difficult to absorb orally, the commonly used solutions in current research reports are: ① Design nano-preparations, such as polymer micelles, polymer nanoparticles, liposome nanoparticles, lipid-polymer hybrid nanoparticles, nanoemulsions and other nano-delivery systems to improve the solubility of paclitaxel; ② Use polymer carriers with P-gp inhibitory activity to deliver drugs, or use them in combination with P-gp inhibitors (such as cyclosporine A, verapamil, etc.) to improve the oral absorption of drugs. However, P-gp inhibitors (such as cyclosporine A, verapamil, etc.) themselves have pharmacological activity and may cause side effects. In addition, the above methods still cannot overcome the physiological and biochemical barriers to the absorption of paclitaxel through the gastrointestinal tract. Therefore, the development of new drug delivery technologies to improve the solubility and dissolution rate of paclitaxel, overcome various physiological and biochemical barriers of the gastrointestinal tract, and thus improve the oral bioavailability of paclitaxel is the focus and difficulty of current research by pharmacists. Summary of the invention

[0005] In order to solve the problem of poor water solubility and oral absorption of paclitaxel, the present invention adopts amorphous solid dispersion drug delivery technology, selects the carrier and surfactant of amorphous solid dispersion, optimizes the prescription and process technology, and can significantly improve the oral bioavailability of paclitaxel. Therefore, the purpose of the present invention is to provide a paclitaxel amorphous solid dispersion oral preparation and a preparation method thereof, by selecting a class of suitable polymer materials and a class of suitable surfactants as carriers for preparing paclitaxel amorphous solid dispersions, and adopting a suitable method to make the drug uniformly dispersed in the excipient in an amorphous state, thereby improving the dissolution and absorption behavior of the drug in the gastrointestinal tract.

[0006] To achieve the above object, the present invention adopts the following technical solutions:

[0007] In a first aspect, the present invention provides a paclitaxel amorphous solid dispersion oral preparation, which is as follows Ⅰ) or Ⅱ):

[0008] Ⅰ) contains paclitaxel and cocamidopropyl betaine;

[0009] II) contains paclitaxel, vitamin E polyethylene glycol succinate and cocamidopropyl betaine.

[0010] Based on this, the present invention selects a zwitterionic surfactant cocamidopropyl betaine (CAPB) as a carrier of paclitaxel, or uses a combination of a polymer material vitamin E polyethylene glycol succinate (vitamin ED-α-tocopheryl polyethylene glycol 1000succinate, TPGS) and a zwitterionic surfactant cocamidopropyl betaine (CAPB) as a carrier of paclitaxel.

[0011] TPGS is a water-soluble vitamin E derivative, consisting of a polar polyethylene glycol (PEG) head and a non-polar vitamin E tail. Due to its amphiphilic structure, TPGS can carry hydrophobic drugs. Due to the presence of its hydrophilic head, it can reduce the affinity with the mononuclear phagocyte system MPS, and can be stably present in the circulation system and prolong the half-life. At the same time, TPGS has the activity of inhibiting the efflux transporter P-gp, reducing the efflux effect of intestinal epithelial cells, thereby promoting the absorption of drugs through the gastrointestinal tract.

[0012] CAPB is a zwitterionic surfactant with quaternary ammonium groups in its molecular structure. CAPB has a weak affinity for mucin in the mucus layer covering the surface of gastrointestinal epithelial cells, so the drugs carried by CAPB can easily pass through the mucus layer, reach the surface of intestinal epithelial cells and be absorbed by the cells.

[0013] Since TPGS and CAPB are used as carriers in combination, the nanoparticles formed after the paclitaxel / TPGS / CAPB amorphous solid dispersion is dissolved in water have good mucus permeability and can also reduce the efflux activity of P-gp, so that the drug absorption through the gastrointestinal tract is significantly increased. In addition, the nanoparticles can change the intestinal absorption mechanism of drug molecules, and can be transported and absorbed through the lymphatic system through the Peyer's patch on the intestinal surface, and the drug absorbed through the lymph can avoid liver metabolism. Therefore, the paclitaxel amorphous solid dispersion preparation of the present invention can significantly improve the oral bioavailability of paclitaxel.

[0014] In the above-mentioned paclitaxel amorphous solid dispersion oral preparation, further, the mass percentage of paclitaxel in the oral preparation is 9% to 17%;

[0015] The mass percentage of the vitamin E polyethylene glycol succinate in the oral preparation is 0% to 45.5%;

[0016] The mass percentage of the cocamidopropyl betaine in the oral preparation is 45.5% to 83%.

[0017] That is, the mass ratio of the paclitaxel, the vitamin E polyethylene glycol succinate and the cocamidopropyl betaine in the oral preparation is 1:(0-5):(3-5).

[0018] In the first embodiment of the present invention, the mass percentage of paclitaxel in the oral preparation is 17%;

[0019] The mass percentage of the cocamidopropyl betaine in the oral preparation is 83%.

[0020] That is, the mass ratio of the paclitaxel to the cocamidopropyl betaine in the oral preparation is 1:5.

[0021] In the second embodiment of the present invention, the mass percentage of paclitaxel in the oral preparation is 17%;

[0022] The mass percentage of the vitamin E polyethylene glycol succinate in the oral preparation is 33%;

[0023] The mass percentage of the cocamidopropyl betaine in the oral preparation is 50%.

[0024] That is, the mass ratio of the paclitaxel, the vitamin E polyethylene glycol succinate and the cocamidopropyl betaine in the oral preparation is 1:2:3.

[0025] In the third embodiment of the present invention, the mass percentage of paclitaxel in the oral preparation is 12.5%;

[0026] The mass percentage of the vitamin E polyethylene glycol succinate in the oral preparation is 25%;

[0027] The mass percentage of the cocamidopropyl betaine in the oral preparation is 62.5%.

[0028] That is, the mass ratio of the paclitaxel, the vitamin E polyethylene glycol succinate and the cocamidopropyl betaine in the oral preparation is 1:2:5.

[0029] In the fourth embodiment of the present invention, the mass percentage of paclitaxel in the oral preparation is 9%;

[0030] The mass percentage of the vitamin E polyethylene glycol succinate in the oral preparation is 45.5%;

[0031] The mass percentage of the cocamidopropyl betaine in the oral preparation is 45.5%.

[0032] That is, the mass ratio of the paclitaxel, the vitamin E polyethylene glycol succinate and the cocamidopropyl betaine in the oral preparation is 1:5:5.

[0033] Among them, in the third embodiment, the dosage of CAPB in the preparation was further increased, and the oral bioavailability of paclitaxel / TPGS / CAPB (1:2:5, w / w / w) (F7) was significantly improved. However, on the basis of the third embodiment, when the content of TPGS in the preparation was further increased, the oral bioavailability of paclitaxel / TPGS / CAPB (1:5:5, w / w / w) (F8) was reduced, indicating that the content of TPGS should be controlled within a certain range. It can be seen from the pharmacokinetic parameters of paclitaxel in different formulation groups in Table 1 that when the mass ratio of paclitaxel to cocamidopropyl betaine is 1:5, its absolute bioavailability (F%) is 45.61%, which is higher than the absolute bioavailability of paclitaxel / TPGS / CAPB (1:2:3, w / w / w), and the absolute oral bioavailability of paclitaxel / TPGS / CAPB (1:2:5, w / w / w) and paclitaxel / TPGS / CAPB (1:5:5, w / w / w) is higher.

[0034] Further, preferably, the mass percentage of paclitaxel in the oral preparation is 17%;

[0035] The mass percentage of the cocamidopropyl betaine in the oral preparation is 83%.

[0036] Furthermore, preferably, the mass percentage of paclitaxel in the oral preparation is 9% to 12.5%;

[0037] The mass percentage of the vitamin E polyethylene glycol succinate in the oral preparation is 25% to 45.5%;

[0038] The mass percentage of the cocamidopropyl betaine in the oral preparation is 45.5% to 62.5%.

[0039] More preferably, the mass percentage of paclitaxel in the oral preparation is 12.5%;

[0040] The mass percentage of the vitamin E polyethylene glycol succinate in the oral preparation is 25%;

[0041] The mass percentage of the cocamidopropyl betaine in the oral preparation is 62.5%.

[0042] In the above-mentioned paclitaxel amorphous solid dispersion oral preparation, further, in the oral preparation, paclitaxel, vitamin E polyethylene glycol succinate and cocamidopropyl betaine are all in amorphous state.

[0043] In the above-mentioned paclitaxel amorphous solid dispersion oral preparation, the mass percentage of paclitaxel in the oral preparation is calculated as the mass percentage of paclitaxel crystalline bulk drug in the oral preparation.

[0044] In the above-mentioned paclitaxel amorphous solid dispersion oral preparation, the molecular formula of the vitamin E polyethylene glycol succinate is C 33 H 54 O5·(C2H4O) n ,CAS No.: 9002-96-4; the mass percentage of the vitamin E polyethylene glycol succinate in the oral preparation is calculated based on the mass percentage of reagent grade vitamin E polyethylene glycol succinate in the oral preparation.

[0045] In the above-mentioned paclitaxel amorphous solid dispersion oral preparation, as an example, the solid content of the cocamidopropyl betaine is 95% (reagent grade). The mass percentage of the cocamidopropyl betaine in the oral preparation is calculated based on the mass percentage of the cocamidopropyl betaine in the oral preparation of the solid content.

[0046] In a second aspect, the present invention provides a method for preparing the paclitaxel amorphous solid dispersion oral preparation described in any one of the above, which is as follows 1) or 2):

[0047] 1) comprising the following steps: uniformly dispersing paclitaxel in cocamidopropyl betaine to obtain the paclitaxel amorphous solid dispersion oral preparation;

[0048] 2) comprising the following steps: uniformly dispersing paclitaxel in two auxiliary materials, vitamin E polyethylene glycol succinate and cocamidopropyl betaine, to obtain the paclitaxel amorphous solid dispersion oral preparation.

[0049] Furthermore, the dispersion step in the method 1) is as follows: dissolving paclitaxel and cocamidopropyl betaine in an organic solvent to prepare a drug solution, and removing the organic solvent in the drug solution;

[0050] The dispersion step in the method 2) is as follows: paclitaxel, vitamin E polyethylene glycol succinate and cocamidopropyl betaine are dissolved in an organic solvent to prepare a drug solution, and then the organic solvent in the drug solution is removed.

[0051] Furthermore, the solvent is ethanol; the method of removing the solvent can be a suitable solvent volatilization method such as spray drying or rotary evaporation.

[0052] In the present invention, the dispersing step may also be to directly mix paclitaxel with vitamin E polyethylene glycol succinate and cocamidopropyl betaine and then melt extrude the mixture, so that the drug is highly dispersed in the preparation.

[0053] The present invention has the following beneficial effects:

[0054] ① Significantly improve the oral bioavailability of paclitaxel. The paclitaxel preparation was orally administered (40 mg / kg) to Sprague-Dawley male rats (180-200 g). The oral bioavailability of paclitaxel crystalline raw materials directly orally orally with injection preparations (paclitaxel / Cremophor EL) was very low, and the maximum blood concentration (C max ) is less than 40ng / mL, and the absolute bioavailability is less than 2%. However, the present invention optimizes the ratio of paclitaxel and excipients, and after a single oral administration of paclitaxel / TPGS / CAPB amorphous solid dispersion, the drug C max It can be as high as ~3788ng / mL, and F% is as high as 86.4%, and the oral bioavailability of paclitaxel is greatly improved.

[0055] Since TPGS and CAPB have good compatibility with paclitaxel, they can form strong drug-excipient molecular interactions. In the paclitaxel / TPGS / CAPB amorphous solid dispersion, the drug is dispersed in the excipient in a molecular state, and the excipient can effectively inhibit the recrystallization of the amorphous drug and significantly improve the solubility and dissolution rate of the drug in water. In vitro experimental studies have shown that the solubility of paclitaxel crystals in water is 0.12μg / mL. The paclitaxel / TPGS / CAPB amorphous solid dispersion of the present invention is administered to rats at a drug concentration of 4mg / mL. The drug is completely dissolved in water and can remain in a supersaturated state for a long time, and the drug does not recrystallize. In addition, the paclitaxel / TPGS / CAPB amorphous solid dispersion is dissolved in water to form very small and uniform nanoparticles, which can change the drug absorption mechanism through the intestine and avoid the first-pass effect of the liver. At the same time, the introduction of TPGS and CAPB can increase the drug's ability to penetrate the mucus layer on the surface of gastrointestinal epithelial cells and inhibit the efflux of P-gp drugs, thereby overcoming a series of physiological and biochemical barriers to the absorption of paclitaxel through the gastrointestinal tract. Animal in vivo experiments have shown that this formulation design is very conducive to the absorption of paclitaxel through the intestine.

[0056] ② The preparation process of the preparation is simple and the quality is controllable. Since the paclitaxel, TPGS and CAPB in the present invention are all easily soluble in ethanol solvent, it is only necessary to dissolve the drug and excipients together in ethanol solvent, and remove the solvent by simple spray drying or rotary evaporation and other techniques to prepare a uniform paclitaxel / TPGS / CAPB amorphous solid dispersion. The solvent used is also very green and environmentally friendly, reducing the harm to the human body and the environment. In addition, since TPGS is a good plasticizer, it can significantly reduce the glass transition temperature (T g ), therefore, the paclitaxel preparation of the present invention can also be prepared by hot melt extrusion. In the paclitaxel / TPGS / CAPB amorphous solid dispersion, the drug and the excipients can form a strong intermolecular interaction. Therefore, during the preparation, storage, and in vitro and in vivo dissolution of the preparation, the excipients can effectively inhibit the recrystallization of paclitaxel, so that the drug maintains an amorphous state and a supersaturated state, and increases the physical stability and in vivo absorption behavior of the preparation.

[0057] ③ Low toxicity. The TPGS used in the present invention is very safe and can be used for intravenous administration. CAPB is also very safe and can be used for skin administration preparations. The paclitaxel / TPGS / CAPB amorphous solid dispersion prepared by the present invention was administered to rats by gavage, and no adverse reactions were found in rats. In the acute toxicity experiment on mice, no toxic dose was measured. BRIEF DESCRIPTION OF THE DRAWINGS

[0058] Figure 1 The PXRD spectra of CAPB (A), TPGS (B), paclitaxel crystals (C), paclitaxel / TPGS oily micelles (D), and paclitaxel / TPGS / CAPB amorphous solid dispersion (E) in Example 1 are shown.

[0059] Figure 2 Physical structure characterization of nanoparticles formed after dissolving the paclitaxel / TPGS / CAPB amorphous solid dispersion in water in Example 1: a) dynamic light scattering to measure the particle size of the nanoparticles; b) dynamic light scattering to measure the ζ-potential of the nanoparticles; c) transmission electron microscopy image of the nanoparticles.

[0060] Figure 3 The drug-time curve of paclitaxel in the F2, F3, and F4 preparation groups (the embedded figure is an enlarged view of 0-4h).

[0061] Figure 4 The drug-time curve of paclitaxel in the F1, F5, F6, F7, and F8 preparation groups (the embedded figure is an enlarged view of 0-4h). DETAILED DESCRIPTION

[0062] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.

[0063] The methods used in the following examples, unless otherwise specified, are all conventional methods, carried out according to the techniques or conditions described in the literature in the art or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial sources.

[0064] The paclitaxel in the following embodiments is all paclitaxel crystalline API, which is a product of Wuhan Belle Biopharmaceutical Technology Co., Ltd., and has a solid content of more than 99%.

[0065] The TPGS in the following examples is a product of Shanghai MacLean Biochemical Technology Co., Ltd., the product name is vitamin E polyethylene glycol succinate, reagent grade, and the product number is Lot: C15168997.

[0066] The CAPB in the following examples is a product of Shanghai MacLean Biochemical Technology Co., Ltd., the product name is cocamidopropyl betaine, reagent grade, product number is Lot: C16478324, and the solid content is 95%.

[0067] Example 1

[0068] This embodiment provides a paclitaxel / TPGS / CAPB amorphous solid dispersion oral preparation group, and the preparation steps are as follows: paclitaxel, TPGS, and CAPB are dissolved in an ethanol solvent at a weight ratio of 1:2:3 (w / w / w), 1:2:5 or 1:5:5 (w / w / w), and the solvent is removed by a rotary evaporator to prepare a paclitaxel / TPGS / CAPB amorphous solid dispersion.

[0069] Comparative Example 1

[0070] This comparative example provides a paclitaxel crystal drug preparation group, and the preparation steps are as follows: weigh the paclitaxel crystal drug. Dissolve sodium carboxymethyl cellulose in pure water to prepare a sodium carboxymethyl cellulose solution with a concentration of 0.5%. Add the paclitaxel crystal drug to the sodium carboxymethyl cellulose suspension to obtain a 4 mg / mL paclitaxel crystal drug suspension.

[0071] Comparative Example 2

[0072] This comparative example provides a replica The preparation group was prepared as follows: Paclitaxel and Cremophor EL (Shanghai MacLean Biochemical Technology Co., Ltd.) were dissolved in ethanol solvent at a weight ratio of 1:10 (w / w), and the solvent was removed by rotary evaporator to prepare Paclitaxel / Cremophor EL oily micelles, i.e., preparation.

[0073] Comparative Example 3

[0074] This comparative example provides a paclitaxel / TPGS preparation group, and the preparation steps are as follows: paclitaxel and TPGS are dissolved in an ethanol solvent at a weight ratio of 1:10 (w / w), and the solvent is removed by a rotary evaporator to prepare paclitaxel / TPGS oily micelles.

[0075] Example 2

[0076] This example provides a paclitaxel / CAPB preparation set, and the preparation steps are as follows: dissolving paclitaxel and CAPB in an ethanol solvent at a weight ratio of 1:5 (w / w), and removing the solvent using a rotary evaporator to prepare a paclitaxel / CAPB amorphous solid dispersion.

[0077] Depend on Figure 1 As can be seen from the PXRD patterns of each group in the present embodiment, paclitaxel, TPGS and CAPB are all amorphous. PTX, TPGS and CAPB raw materials all have characteristic crystal diffraction peaks, while in paclitaxel / TPGS or paclitaxel

[0078] In the / TPGS / CAPB preparation, these crystal diffraction peaks disappeared.

[0079] Depend on Figure 2 It can be seen that the paclitaxel / TPGS / CAPB amorphous solid dispersion can significantly improve the solubility and dissolution rate of paclitaxel. After the preparation is dissolved in water, it will form uniform nanoparticles with a particle size of ~7.5nm and a Zeta potential of -4.3mV. After the amorphous solid dispersion is dissolved in water, paclitaxel is encapsulated in the TPGS / CAPB carrier, which can prevent paclitaxel from contacting gastrointestinal metabolic enzymes and reduce drug metabolic degradation. At the same time, this nanostructure can also inhibit the recrystallization of paclitaxel, increase the physical stability of the drug, and maintain the maximum supersaturation of the drug in water.

[0080] TPGS has the activity of inhibiting the efflux transporter P-gp, reducing the efflux effect of intestinal epithelial cells, thereby promoting the absorption of drugs through the gastrointestinal tract. CAPB is a zwitterionic surfactant with strong surface activity and is easier to pass through the mucus layer. TPGS and CAPB are used together as carriers to prepare paclitaxel / TPGS / CAPB amorphous solid dispersions. We speculate that the nanoparticles formed after dissolving in water have good mucus permeability and can also reduce the efflux activity of P-gp. Therefore, the absorption of drugs through the gastrointestinal tract is significantly increased. In addition, nanoparticles can change the intestinal absorption mechanism of drug molecules, and can be transported and absorbed through the lymphatic system through the Peyer's patches on the surface of the intestine. Drugs absorbed by the lymph can avoid liver metabolism. Due to the above reasons, the paclitaxel amorphous solid dispersion designed by the present invention can significantly improve the oral bioavailability of paclitaxel.

[0081] Test Example 1

[0082] Using SD rats as animal models, liquid chromatography-mass spectrometry technology, and acetaminophen as an internal standard, the oral pharmacokinetics of paclitaxel were studied to verify the effect of paclitaxel / TPGS / CAPB amorphous solid dispersion preparation on improving the oral absorption of paclitaxel. Among them, the high-performance liquid chromatography-mass spectrometer used was 5500QTRAP of AB SCIEX Company of the United States, the chromatographic column used was ACQUITY UPLC BEHC18 (1.7μm, 2.1mm X 150mm), the injection volume was 5μL; the flow rate was 0.2mL / min; the column temperature was 40℃; the mobile phases were A (water, 0.1% formic acid) and B (acetonitrile); the elution gradient was shown in Table 2, the separation degree and separation time of PTX and its internal standard (acetaminophen) were investigated, and the appropriate LC-MS chromatographic separation conditions were determined. In the mass spectrometry conditions, an electrospray ion source and multiple reaction monitoring (MRM) positive ion mode were used to investigate and determine the mass spectrometry detection parameters of PTX and APAP, as shown in Table 3. The pharmacokinetic study data were analyzed by DAS2.0 using the statistical moment method to calculate the main pharmacokinetic parameters, including the peak time (T max ) and peak concentration (C max) The measured values ​​were used. GraphPad Prism7 software was used for statistical analysis, and the parameters of each group were expressed as mean ± standard deviation. Pharmacokinetic parameters were calculated according to the non-compartmental model. The absolute bioavailability F (%) was calculated according to the normalized AUC ratio, i.e. (AUCP.O×DOSAGEI.V. / AUC IV×DOSAGEP.O), and the meanings of each physical quantity are as follows: AUCP.O is the area under the curve of the oral preparation group, DOSAGEI.V. is the dosage of the intravenous preparation group, AUC IV is the area under the curve of the intravenous preparation group, and DOSAGEP.O is the dosage of the oral preparation group.

[0083] Sprague-Dawley male rats (180-200 g) were used to Preparations for intravenous injection (F1), paclitaxel crystals for oral administration (F2), generic Oral administration of the preparation (F3), oral administration of paclitaxel / TPGS (1:10, w / w) (F4), oral administration of paclitaxel / CAPB (1:5, w / w) (F5), oral administration of paclitaxel / TPGS / CAPB (1:2:3, w / w / w) (F6), oral administration of paclitaxel / TPGS / CAPB (1:2:5, w / w / w) (F7), and oral administration of paclitaxel / TPGS / CAPB (1:5:5, w / w / w) (F8) were tested for blood drug concentration and pharmacokinetic study. The specific operations are as follows:

[0084] Before use, copy The preparation was prepared with physiological saline to a paclitaxel concentration of 4 mg / mL. In the intravenous injection group, 0.5 mL of the drug solution was injected into the tail vein of each SD rat, equivalent to a dosage of 10 mg / kg, recorded as preparation group F1. In the oral administration group, 2 mL of the drug solution was gavaged into each SD rat, equivalent to a dosage of 40 mg / kg, recorded as preparation group F3. Blood was collected from the posterior ocular venous plexus at a predetermined time for analysis of the corresponding blood drug concentration.

[0085] Before use, the paclitaxel crystal raw material was suspended with 0.5% sodium carboxymethylcellulose to prepare a paclitaxel suspension with a concentration of 4 mg / mL. Each SD rat was gavaged with 2 mL of the drug solution, equivalent to a dosage of 40 mg / kg, recorded as preparation group F2. Blood was collected from the posterior ocular venous plexus at a predetermined time for analysis of the corresponding blood drug concentration.

[0086] Before use, copy The preparation was prepared with pure water to prepare a paclitaxel solution with a concentration of 4 mg / mL, and each SD rat was gavaged with 2 mL of the drug solution, equivalent to a dosage of 40 mg / kg, recorded as preparation group F3. Blood was collected from the posterior ocular venous plexus at a predetermined time for analysis of the corresponding blood drug concentration.

[0087] Before use, the paclitaxel / TPGS (1:10, w / w) micelle preparation was prepared with pure water to a paclitaxel concentration of 4 mg / mL. Each SD rat was gavaged with 2 mL of the drug solution, equivalent to a dosage of 40 mg / kg, recorded as preparation group F4. Blood was collected from the posterior ocular venous plexus at a predetermined time for analysis of the corresponding blood drug concentration.

[0088] Before use, the paclitaxel / CAPB amorphous solid dispersion was dissolved in pure water to prepare a paclitaxel solution with a concentration of 4 mg / mL. Each SD rat was gavaged with 2 mL of the drug solution, equivalent to a dosage of 40 mg / kg, and recorded as preparation group F5. Blood was collected from the posterior ocular venous plexus at a predetermined time for analysis of the corresponding blood drug concentration.

[0089] The paclitaxel / TPGS / CAPB weight ratio of 1:2:3 (w / w / w) was recorded as F6, the paclitaxel / TPGS / CAPB weight ratio of 1:2:5 (w / w / w) was recorded as F7, and the paclitaxel / TPGS / CAPB weight ratio of 1:5:5 (w / w / w) was recorded as F8. Before use, the above three different ratios of paclitaxel / TPGS / CAPB amorphous solid dispersions were dissolved in pure water to prepare a solution with a paclitaxel concentration of 4 mg / mL. Each SD rat was gavaged with 2 mL of the drug solution, equivalent to a dosage of 40 mg / kg. Blood was collected from the posterior ocular venous plexus at a predetermined time for analysis of the corresponding blood drug concentration.

[0090] The plasma drug concentration-time curves of SD rats after administration in each preparation group are as follows Figure 3 The pharmacokinetic parameters are summarized in Table 1.

[0091] Table 1 Pharmacokinetic parameters of paclitaxel in different formulation groups (n=6, M±SD)

[0092]

[0093] Table 2 Paclitaxel gradient elution program

[0094] Time (min) Water (0.1% formic acid) A (%) Acetonitrile B(%) 0 85 15 1.0 80 20 7.0 20 80 10.0 5 95 12.0 85 15

[0095] Table 3 Main mass spectrometry detection parameters

[0096]

[0097] Depend on Figure 3-4 As can be seen from Table 1, the oral bioavailability of paclitaxel API is extremely low (F2), and the maximum blood concentration (C max ) is only 7.3ng / mL, and the absolute bioavailability (F%) is only 0.2%. The oral bioavailability of paclitaxel is still very low. max The concentration of paclitaxel / TPGS preparation (F4) prepared with only TPGS as carrier was only 58.2 ng / mL, and the F% was only 1.3%. Formulation (F3) had similar oral bioavailability, C max The oral bioavailability of paclitaxel / CAPB amorphous solid dispersion (F5) prepared with CAPB as carrier was improved compared with F4. max The oral bioavailability of paclitaxel / TPGS / CAPB (1:2:3, w / w / w) (F6) was significantly improved. max The oral bioavailability of the drug was greatly improved if the dosage of CAPB in the preparation was further increased. The oral absorption effect of paclitaxel / TPGS / CAPB (1:2:5, w / w / w) (F6) was very good. max As high as 3788.2ng / mL, F% as high as 86.4%. However, if the TPGS content is further increased on the basis of F7, the oral bioavailability of the drug cannot be further improved. max The concentration of TPGS and CAPB in paclitaxel preparations should be controlled within a reasonable range to achieve the maximum effect.

[0098] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, can implement the present invention in a wider range under equivalent parameters, concentrations and conditions. Although the present invention provides specific embodiments, it should be understood that the present invention can be further improved. In a word, according to the principle of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departing from the disclosed scope in the application and the changes made with conventional techniques known in the art.

Claims

1. A paclitaxel amorphous solid dispersion oral preparation, characterized in that: It is as follows Ⅰ) or Ⅱ): Ⅰ) contains paclitaxel and cocamidopropyl betaine; II) contains paclitaxel, vitamin E polyethylene glycol succinate and cocamidopropyl betaine.

2. The paclitaxel amorphous solid dispersion oral preparation according to claim 1, characterized in that: The mass percentage of paclitaxel in the oral preparation is 9% to 17%; The mass percentage of the vitamin E polyethylene glycol succinate in the oral preparation is 0% to 45.5%; The mass percentage of the cocamidopropyl betaine in the oral preparation is 45.5% to 83%.

3. The paclitaxel amorphous solid dispersion oral preparation according to claim 1, characterized in that: The mass percentage of paclitaxel in the oral preparation is 17%; The mass percentage of the cocamidopropyl betaine in the oral preparation is 83%.

4. The paclitaxel amorphous solid dispersion oral preparation according to claim 1, characterized in that: The mass percentage of paclitaxel in the oral preparation is 9% to 12.5%; The mass percentage of the vitamin E polyethylene glycol succinate in the oral preparation is 25% to 45.5%; The mass percentage of the cocamidopropyl betaine in the oral preparation is 45.5% to 62.5%.

5. The paclitaxel amorphous solid dispersion oral preparation according to claim 1, characterized in that: The mass percentage of paclitaxel in the oral preparation is 12.5%; The mass percentage of the vitamin E polyethylene glycol succinate in the oral preparation is 25%; The mass percentage of the cocamidopropyl betaine in the oral preparation is 62.5%.

6. The paclitaxel amorphous solid dispersion oral preparation according to claim 1, characterized in that: The mass percentage of paclitaxel in the oral preparation is 9%; The mass percentage of the vitamin E polyethylene glycol succinate in the oral preparation is 45.5%; The mass percentage of the cocamidopropyl betaine in the oral preparation is 45.5%.

7. The paclitaxel amorphous solid dispersion oral preparation according to claim 1, characterized in that: In the oral preparation, paclitaxel, vitamin E polyethylene glycol succinate and cocamidopropyl betaine are all in amorphous state.

8. The method for preparing the paclitaxel amorphous solid dispersion oral preparation according to any one of claims 1 to 7, characterized in that: It is as follows 1) or 2): 1) comprising the following steps: uniformly dispersing paclitaxel in cocamidopropyl betaine to obtain the paclitaxel amorphous solid dispersion oral preparation; 2) comprising the following steps: uniformly dispersing paclitaxel in two auxiliary materials, vitamin E polyethylene glycol succinate and cocamidopropyl betaine, to obtain the paclitaxel amorphous solid dispersion oral preparation.

9. The method for preparing the paclitaxel amorphous solid dispersion oral preparation according to claim 8, characterized in that: The dispersion step in the method 1) is as follows: dissolving paclitaxel and cocamidopropyl betaine in an organic solvent to prepare a drug solution, and removing the organic solvent in the drug solution; The dispersion step in the method 2) is as follows: dissolving paclitaxel, vitamin E polyethylene glycol succinate and cocamidopropyl betaine in an organic solvent to prepare a drug solution, and removing the organic solvent in the drug solution.

10. The method for preparing the paclitaxel amorphous solid dispersion oral preparation according to claim 9, characterized in that: The solvent is ethanol; The method of removing the solvent is solvent volatilization method.

Citation Information

Patent Citations

  • Solid dispersions

    CN107529758A

  • Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof

    US20040092428A1

  • Paclitaxel pharmaceutical composition and pharmaceutical preparation thereof, preparation process and use thereof

    US20190038592A1

Cited By

  • Paclitaxel drug oral pharmaceutical composition, preparation, and preparation method and application of paclitaxel drug oral pharmaceutical composition

    CN119770478A

  • Amorphous tigorazan tablet and preparation method thereof

    CN121570429A

  • Paclitaxel inclusion compound as well as preparation method and application thereof

    CN122499320A